Effects of Porcine Circovirus Type 2 (PCV2) Maternal Antibodies on Experimental Infection of Piglets with PCV2

N. E. McKeown,¹ T. Opriessnig,² P. Thomas,² D. K. Guenette,¹ F. Elvinger,¹ M. Fenaux,¹ P. G. Halbur,² and X. J. Meng¹*

Center for Molecular Medicine and Infectious Diseases, College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia,¹ and Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa²

Received 14 April 2005/Returned for modification 26 July 2005/Accepted 13 September 2005

Porcine circovirus (PCV) was initially isolated as a persistent contaminant of the porcine kidney PK-15 cell line (25). PCV is a ubiquitous virus that does not cause any disease in piglets (3, 26). Recently, a new swine disease named postweaning multisystemic wasting syndrome (PMWS) (14) was linked to PCV infection. The PMWS-associated PCV was designated PCV type 2 (PCV2), whereas the nonpathogenic PK-15 cell-derived PCV was designated PCV1 (2, 7). PCV2, a member of the family Circoviridae (27), is a nonenveloped, single-stranded DNA virus of 1,768 bp (1, 2, 5, 7, 13). The ORF2 gene of PCV2 encodes the major capsid protein that contains neutralizing epitopes (5, 10, 12, 16), whereas the ORF1 gene encodes Rep proteins that are involved in virus replication (5, 13). The genetic determinant for PCV2 virulence is not known (5), although two amino acids in the capsid gene are involved in PCV2 attenuation (10).

PMWS mainly affects 5- to 16-week-old pigs (2, 14, 23). The characteristic clinical symptoms of PMWS include progressive weight loss, dyspnea, enlargement of lymph nodes, diarrhea, pallor, and jaundice (2, 23). The hallmark microscopic lesions in PCV2-infected pigs are lymphoid depletion and histiocytic replacement of lymphoid follicles (2, 23). Piglets coinfected with PCV2 and porcine parvovirus, PCV2 and porcine reproductive and respiratory syndrome virus, or PCV2 and Mycoplasma hyopneumoniae had more severe clinical disease and PCV2-associated lesions than piglets infected with PCV2 (4, 6, 15, 19, 20, 22). A vaccine against PCV2 is not yet available, although an experimental vaccine based on a chimeric virus of PCV1 and PCV2 is very promising (8, 9, 11).

To determine the effects of porcine circovirus type 2 (PCV2) maternal antibodies on and response to experimental PCV2 infection, 24 piglets were divided into four groups on the basis of the enzyme-linked immunosorbent assay titers of PCV2 maternal antibodies: group A (n = 6; sample/positive [S/P] ratio, <0.2), group B (n = 5; S/P ratio, >0.2 to <0.5), and groups C (n = 8) and D (n = 5) (S/P ratio, >0.5). Piglets in groups A, B, and C were inoculated with PCV2 at day 0 and challenged with PCV2 at day 42. Group D piglets were not exposed to PCV2 at day 0 but were challenged at day 42. Before challenge, seroconversion to PCV2 antibodies occurred in five of six group A piglets, and the antibody level rose above the cutoff level in one of five group B piglets. Viremia was detected in five of six, four of five, and two of eight pigs in groups A, B, and C, respectively. After challenge, PCV2 DNA was detectable from 7 to 21 days postchallenging in the sera from six, four of five, and five of eight pigs in groups A, B, and C, respectively. The results indicated that protection against PCV2 infection conferred by maternal antibodies is titrate dependent: higher titers are generally protective, but low titers are not.
placed in group A, and five piglets with maternal antibodies at
an S/P ratio between 0.2 and 0.5 were placed in group B. Of the
13 pigs with maternal antibodies at an S/P ratio of >0.5, 8 were
assigned to group C and 5 to group D (Table 1). The ELISA
S/P ratio cutoff is determined to be 0.2 (17); therefore, piglets
at an S/P ratio <0.2 are considered negative for maternal
antibodies. Piglets with an S/P ratio of >0.2 to <0.5 are con-
sidered to have a low level of detectable maternal antibodies,
whereas piglets with an S/P ratio of >0.5 have a high level of
maternal antibodies (18).

An infectious PCV2 virus stock was generated by transfect-
ing PK-15 cells with a PCV2 infectious DNA clone (8–11), and
the infectivity titer of the PCV2 virus stock was subsequently
determined as previously described (8–11) and used for the
animal experiment. Piglets from groups A, B, and C (Table 1)
were all exposed to PCV2 at day 0: each received 3 ml (1 × 107.55
50% tissue culture infective doses) of PCV2 by slow
instillation into the nasal cavity. Piglets in group D were not
exposed to PCV2 at day 0 (Table 1). Piglets in groups A, B, C,
and D were all challenged with 3 ml (1 × 104.7 50% tissue
culture infective doses) of a homologous PCV2 at 42 days
postinoculation (dpi). To maximize the exposure of pigs to
PCV2 challenge, approximately 1 ml of inoculum was given
intramuscularly, and 2 ml was given intranasally. All piglets
were bled prior to inoculation and weekly thereafter, and nec-
ropsied at 21 days postchallenge (dpi).

Viremia and PCV2 DNA load in sera were determined by a
modified quantitative PCR, and the standardization of the
assay has previously been described (9–11). A standard dilu-
tion series with a known amount of plasmid containing a single
copy of the PCV2 genome was run simultaneously with sam-
ples in each reaction (9, 11). After amplification, a melt curve
analysis was performed to assure the correct product was
formed. Quantification of viral genomic copies per milliliter
(GC/ml) of serum was then carried out essentially as previously
described (17). Serum viral DNA loads (number of genomic copies per milliliter of serum) in pigs at the indicated day postinoculation (dpi) or day postchallenge (dpc).

<table>
<thead>
<tr>
<th>Group or parameter</th>
<th>Pig IDa</th>
<th>0 dpi</th>
<th>7 dpi</th>
<th>14 dpi</th>
<th>21 dpi</th>
<th>28 dpi</th>
<th>35 dpi</th>
<th>42 dpi</th>
<th>49 dpi</th>
<th>56 dpi</th>
<th>63 dpi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>10</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.6 × 107</td>
<td>1.4 × 107</td>
<td>1.2 × 108</td>
<td>3.2 × 108</td>
<td>3.4 × 108</td>
<td>1.2 × 109</td>
<td>4.7 × 109</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3.0 × 106</td>
<td>5.5 × 106</td>
<td>3.7 × 108</td>
<td>3.1 × 108</td>
<td>1.8 × 108</td>
<td>1.1 × 109</td>
<td>1.5 × 109</td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>6.3 × 106</td>
<td>2.4 × 107</td>
<td>6.2 × 108</td>
<td>2.1 × 108</td>
<td>1.4 × 108</td>
<td>1.2 × 109</td>
<td>8.7 × 109</td>
</tr>
<tr>
<td></td>
<td>47</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.3 × 106</td>
<td>5.0 × 106</td>
<td>1.9 × 108</td>
<td>5.3 × 108</td>
<td>1.7 × 108</td>
<td>2.0 × 108</td>
<td>3.0 × 109</td>
</tr>
<tr>
<td></td>
<td>53</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.8 × 106</td>
<td>6.3 × 106</td>
<td>1.0 × 108</td>
<td>7.8 × 108</td>
<td>3.0 × 108</td>
<td>2.4 × 107</td>
<td>5.6 × 109</td>
</tr>
<tr>
<td>No. of pigs with viremiaa</td>
<td>0/6</td>
<td>0/6</td>
<td>2/6</td>
<td>5/6</td>
<td>5/6</td>
<td>5/6</td>
<td>4/6</td>
<td>6/6</td>
<td>6/6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group B</td>
<td>21</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.0 × 107</td>
<td>3.5 × 107</td>
<td>2.3 × 108</td>
<td>5.8 × 108</td>
<td>3.5 × 108</td>
<td>6.0 × 108</td>
<td></td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4.7 × 106</td>
<td>7.5 × 107</td>
<td>8.7 × 108</td>
<td>1.7 × 108</td>
<td>5.4 × 108</td>
<td>1.9 × 109</td>
<td>8.6 × 109</td>
</tr>
<tr>
<td></td>
<td>43</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4.6 × 106</td>
<td>5.8 × 106</td>
<td>2.5 × 108</td>
<td>1.3 × 108</td>
<td>1.4 × 108</td>
<td>2.2 × 108</td>
<td>2.6 × 109</td>
</tr>
<tr>
<td></td>
<td>71</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>No. of pigs with viremia</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>2/5</td>
<td>4/5</td>
<td>4/5</td>
<td>4/5</td>
<td>4/5</td>
<td>4/5</td>
<td>4/5</td>
<td>4/5</td>
</tr>
<tr>
<td>Group C</td>
<td>9</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.9 × 104</td>
<td>2.3 × 104</td>
<td>5.6 × 106</td>
<td>3.6 × 106</td>
<td>3.6 × 106</td>
<td>9.8 × 106</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.9 × 104</td>
<td>2.3 × 104</td>
<td>5.6 × 106</td>
<td>3.6 × 106</td>
<td>3.6 × 106</td>
<td>9.8 × 106</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.7 × 104</td>
<td>1.7 × 104</td>
<td>3.3 × 106</td>
<td>3.3 × 106</td>
<td>3.3 × 106</td>
<td>7.5 × 106</td>
<td></td>
</tr>
<tr>
<td></td>
<td>34</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>54</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>61</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>68</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>9.2 × 102</td>
<td>4.3 × 103</td>
<td>1.5 × 104</td>
</tr>
<tr>
<td>No. of pigs with viremia</td>
<td>0/8</td>
<td>0/8</td>
<td>0/8</td>
<td>1/8</td>
<td>2/8</td>
<td>2/8</td>
<td>2/8</td>
<td>3/8</td>
<td>3/8</td>
<td>3/8</td>
<td>2/8</td>
</tr>
<tr>
<td>Group D</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.1 × 106</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3.9 × 105</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>81</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.5 × 106</td>
<td>2.1 × 106</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>82</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>7.5 × 106</td>
<td>3.9 × 106</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.2 × 105</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of pigs with viremia</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>0/5</td>
<td>4/5</td>
<td>4/5</td>
<td>4/5</td>
</tr>
</tbody>
</table>

- a Group A, negative maternal antibody (S/P ratio of <0.2); group B, low maternal antibody (S/P ratio of >0.2 to <0.5); groups C and D, high maternal antibody (S/P ratio of >0.5).
- b Pig ID, pig identification number.
- c Serum viral DNA load (number of genomic copies per milliliter of serum) in pigs at the indicated day postinoculation (dpi) or day postchallenge (dpc). –, negative by quantitative PCR.
- d Number of pigs with viremia/total number of pigs in the group.
tested. The low levels of maternal antibodies in group B piglets waned by 14 dpi. At 21 dpi, the five group B piglets had become seronegative (S/P ratio, <0.2) and remained so through 35 dpi. At 42 dpi, one pig in group B (pig 71) seroconverted and the other four pigs were still seronegative (Fig. 1). Viremia was first detected in two of five group B piglets at 21 dpi, and by 42 dpi, four piglets had viremia. The high level of maternal antibodies in group C pigs gradually waned from 7 to 42 dpi, and there was no rise of antibody titer between 7 and 42 dpi in any piglets (Fig. 1). Viremia was detected in one of eight piglets (pig 15) at 21 dpi (Table 1), and by 42 dpi, four piglets had viremia. The high level of maternal antibodies in group C pigs gradually waned from 7 to 42 dpi, and there was no rise of antibody titer between 7 and 42 dpi in any piglets (Fig. 1). Viremia was detected in one of eight piglets (pig 15) at 21 dpi (Table 1), and by 42 dpi, four piglets had viremia. The high level of maternal antibodies in group C pigs gradually waned from 7 to 42 dpi, and there was no rise of antibody titer between 7 and 42 dpi in any piglets (Fig. 1). Viremia was detected in one of eight piglets (pig 15) at 21 dpi (Table 1), and by 42 dpi, four piglets had viremia. Statistical analysis showed that the day of peak viremia in infected piglets was not related to the initial maternal antibody level (P = 0.50). Peak viremia level decreased with increasing maternal antibody levels present at −2 dpi (P = 0.025). The mean antibody level at −2 dpi in the piglets that became infected with PCV2 was lower (S/P ratio, 0.37; standard deviation, 0.328) than in piglets that did not become infected (S/P ratio, 0.84; standard deviation, 0.515) (P = 0.044).

These results suggested that the presence of low levels of PCV2 maternal antibodies does not protect piglets from experimental PCV2 infection and that high levels of PCV2 maternal antibodies generally confer protection against PCV2 infection, but not total protection. Statistical analysis showed that peak viremia levels in piglets were reduced in those piglets with higher antibody levels at the time of inoculation (P = 0.025). When piglets in group D were challenged at day 42, all five piglets became infected. These results could explain why many neonatal piglets born to PCV2-positive sows are still susceptible to PCV2 infection in swine farms under field conditions.

To determine the length of protection that PCV2 maternal antibodies can confer to the piglets and to assess the outcome of prior PCV2 exposure on reinfection of piglets by PCV2, we challenged all piglets with PCV2 at 42 dpi. At the time of challenge, five of six pigs in group A were seropositive in response to the initial PCV2 exposure at dpi 0 (Fig. 1), and four of six piglets were viremic at challenge (Table 1). The maternal antibodies in group B piglets all fell below the S/P ratio cutoff value by 21 dpi, and all but one piglet were seronegative (Fig. 1) and two piglets were viremic at the time of challenge (Table 1). In group C, at the time of challenge at 42 dpi, four piglets were still positive for PCV2 maternal antibodies with S/P ratios ranging from 0.23 to 0.98; the S/P ratios in the other four pigs were all <0.2 (Fig. 1), and two piglets were viremic at the time of challenge (Table 1).

After challenge, PCV2 antibody levels in piglets from groups A and B continued to rise. In contrast, there was no detectable increase in PCV2 antibody levels in group C pigs after challenge. After challenge, all six piglets in group A were viremic.
and had serum viral DNA loads ranging from $10^4$ to $10^6$ GC/ml serum at 7 dpc and from $10^4$ to $10^7$ GC/ml serum at 21 dpc. In group B piglets, four of five piglets remained viremic and had serum viral DNA loads ranging from $10^4$ to $10^7$ GC/ml serum at 7 dpc (Table 1). After challenge, two group C piglets remained viremic with no change in the range of serum viral DNA load, and only one additional piglet, which had a very low S/P ratio at the time of challenge, developed viremia (Table 1). Piglet 71 in group B and piglet 54 in group C showed an increase in antibody titer above the cutoff value after challenge, even though viremia remained undetectable in the two pigs (Fig. 1 and Table 1). This could be explained by localized replication of the virus in lymphoid tissues during the early phase of replication, thus resulting in an undetectable level of viremia. Also, piglet 43 in group B had low but persistent viremia since 28 dpi but was seronegative throughout the study. The relatively low level of viremia could explain the absence of a significant increase of antibody in this pig (Table 1).

The group D piglets were not exposed to PCV2 until day 42, and their maternal antibody level waned gradually over the course of the experiment (Fig. 1). At the time of challenge, all five group D pigs still had low levels of maternal antibodies, with S/P ratios ranging from 0.24 to 0.33. After challenge, there was no detectable rise of PCV2 antibody titer (Fig. 1), but all five group D piglets developed viremia at 14 dpc.

These results showed that the PCV2-exposed piglets with no or low levels of maternal antibodies (groups A and B) were not protected from the homologous challenge by PCV2, as evidenced by continuous viremia despite rising antibody levels. At the time of challenge, five of six group A piglets had already developed an active serum PCV2 antibody response from the initial exposure. Therefore, it is likely that both the humoral immune response and cell-mediated immune response are required for full protection (11). Future studies with PCV2 challenge beyond 42 dpi are needed to fully evaluate the effects of prior PCV2 exposure on homologous PCV2 challenge.

In conclusion, the results from this study indicated that the levels of PCV2 maternal antibodies are an important determinant of a piglet’s response to PCV2 infection. It appears that the higher the levels of maternal antibodies, the more protection the piglets will have. The data from this study have important implications for selecting the optimal timing of vaccination, especially with a live PCV2 vaccine when it becomes available. Since the majority of newborns have PCV2 maternal antibodies, a live PCV2 vaccine will work most efficiently when given to pigs older than 7 to 8 weeks of age, at which time the maternal antibodies have mostly waned.

This study was funded in part by a grant from Fort Dodge Animal Health, Inc., and by a grant from USDA-NRI (2004-35204-14213). We thank S. M. Boyle, L. A. Eng, W. Huckle, S. Tolin, and T. Toth for their support. We also thank Stephen Wu and Mike Gill of Fort Dodge Animal Health for their support.

REFERENCES


